Arabic Arabic English English French French German German
dark

Carb-X awards up to $3m to GenomeKey for rapid sepsis diagnostic

CARB-X is awarding GenomeKey in Bristol up to $3 million in non-dilutive funding to develop a rapid diagnostic for sepsis. GenomeKey is eligible for up to $6.5 million in additional awards if the project achieves certain milestones. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Break the chain of transmission (in Hindi)

Next Post

Pfizer acquires Amplyx Pharmaceuticals

Related Posts
Total
0
Share